{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T09:29:43Z","timestamp":1785317383255,"version":"3.55.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"Supplement_D","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Atrial tachyarrhythmias often occur in patients with worsening heart failure (HF), and the development of atrial tachyarrhythmias in acute decompensated HF (ADHF) causes an uncontrolled heart rate (HR) and leads to further exacerbation of HF and persistence of a decompensated HF state. Landiolol, a short-acting intravenous beta-1 blocker, shows very high cardiac beta-1 selectivity and has a very short elimination half-life of approximately 4\u2005min. As shown in several reports, the benefit of intravenous landiolol is that it lowers the ventricular rate early after the start of use without markedly deteriorating haemodynamics. After the cardiac status is stabilized by rapid control of HR, subsequent basic HF pharmacotherapy and rhythm control therapies will be effective for improving outcomes. Because of the pharmacokinetic properties of landiolol, if the patient suffers an adverse reaction such as hypotension or bradycardia, such effects can be quickly reversed by tapering the dose or discontinuing use altogether. Based on several clinical studies, this review discusses the efficacy, safety and role of intravenous landiolol in acute HR control in patients with atrial tachyarrhythmias and ADHF.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suac023","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T19:21:25Z","timestamp":1648495285000},"page":"D11-D21","source":"Crossref","is-referenced-by-count":13,"title":["Benefits and safety of landiolol for rapid rate control in patients with atrial tachyarrhythmias and acute decompensated heart failure"],"prefix":"10.1093","volume":"24","author":[{"given":"Tsuyoshi","family":"Shiga","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, The Jikei University School of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"2022061314500976500_suac023-B1","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jacc.2009.01.055","article-title":"Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro heart survey on atrial fibrillation","volume":"53","author":"Nieuwlaat","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2022061314500976500_suac023-B2","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1161\/CIRCHEARTFAILURE.115.002285","article-title":"Prognostic significance of resting heart rate and use of \u03b2-blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: findings from the Swedish heart failure registry","volume":"8","author":"Li","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2022061314500976500_suac023-B3","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","article-title":"Impact of atrial fibrillation on the risk of death: The Framingham heart study","volume":"98","author":"Benjamin","year":"1998","journal-title":"Circulation"},{"key":"2022061314500976500_suac023-B4","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1161\/01.CIR.0000072767.89944.6E","article-title":"Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study","volume":"107","author":"Wang","year":"2003","journal-title":"Circulation"},{"key":"2022061314500976500_suac023-B5","doi-asserted-by":"crossref","first-page":"C45","DOI":"10.1093\/eurheartj\/18.suppl_C.45","article-title":"Management of atrial fibrillation in the setting of heart failure","volume":"18","author":"Crijns","year":"1997","journal-title":"Eur Heart J"},{"key":"2022061314500976500_suac023-B6","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1161\/01.CIR.0000132470.78896.A8","article-title":"Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle","volume":"109","author":"Cha","year":"2004","journal-title":"Circulation"},{"key":"2022061314500976500_suac023-B7","first-page":"3250","article-title":"Atrial fibrillation in heart failure: what should we do?","volume":"36","author":"Kotecha","year":"2015","journal-title":"Eur Heart J"},{"key":"2022061314500976500_suac023-B8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/01.CCM.0000048627.39686.79","article-title":"Effectiveness of direct-current cardioversion for treatment of supraventricular tachyarrhythmias, in particular atrial fibrillation, in surgical intensive care patients","volume":"31","author":"Mayr","year":"2003","journal-title":"Crit Care Med"},{"key":"2022061314500976500_suac023-B9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2022061314500976500_suac023-B10","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2022061314500976500_suac023-B11","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1248\/cpb.40.1462","article-title":"Development of a highly cardioselective ultra short-acting beta-blocker. ONO 1101","volume":"40","author":"Iguchi","year":"1992","journal-title":"Chem Pharm Bull"},{"key":"2022061314500976500_suac023-B12","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1093\/eurheartj\/sux037","article-title":"Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting","volume":"20","author":"Domanovits","year":"2018","journal-title":"Eur Heart J Suppl"},{"key":"2022061314500976500_suac023-B13","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40265-013-0077-4","article-title":"Landiolol: a review of its use in intraoperative and postoperative tachyarrhythmias","volume":"73","author":"Plosker","year":"2013","journal-title":"Drugs"},{"key":"2022061314500976500_suac023-B14","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/BF03016588","article-title":"In rabbits, landiolol, a new ultra-short-acting beta-blocker, exerts a more potent negative chronotropic effect and less effect on blood pressure than esmolol","volume":"48","author":"Sasao","year":"2001","journal-title":"Can J Anaesth"},{"key":"2022061314500976500_suac023-B15","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1253\/circj.CJ-12-1618","article-title":"Urgent management of rapid heart rate in patients with atrial fibrillation\/flutter and left ventricular dysfunction: comparison of the ultra-short-acting \u03b2:1.-selective blocker landiolol with digoxin (J-Land Study)","volume":"77","author":"Nagai","year":"2013","journal-title":"Circ J"},{"key":"2022061314500976500_suac023-B16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000355312","article-title":"A low-dose \u03b21-blocker effectively and safely slows the heart rate in patients with acute decompensated heart failure and rapid atrial fibrillation","volume":"127","author":"Kobayashi","year":"2014","journal-title":"Cardiology"},{"key":"2022061314500976500_suac023-B17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00380-013-0377-3","article-title":"Novel use of the ultra-short-acting intravenous \u03b21-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure","volume":"29","author":"Adachi","year":"2014","journal-title":"Heart Vessels"},{"key":"2022061314500976500_suac023-B18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.joa.2015.09.002","article-title":"Practical applicability of landiolol, an ultra-short-acting \u03b21-selective blocker, for rapid atrial and ventricular tachyarrhythmias with left ventricular dysfunction","volume":"32","author":"Wada","year":"2016","journal-title":"J Arrhythm"},{"key":"2022061314500976500_suac023-B19","doi-asserted-by":"crossref","first-page":"426","DOI":"10.14740\/jocmr2954w","article-title":"Efficacy of intravenous administration of landiolol in patients with acute heart failure and supraventricular tachyarrhythmia","volume":"9","author":"Kiuchi","year":"2017","journal-title":"J Clin Med Res"},{"key":"2022061314500976500_suac023-B20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40801-019-0149-1","article-title":"Effects of intravenous landiolol on heart rate and outcomes in patients with atrial tachyarrhythmias and acute decompensated heart failure: a single-center experience","volume":"6","author":"Matsui","year":"2019","journal-title":"Drugs Real World Outcomes"},{"key":"2022061314500976500_suac023-B21","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1253\/circrep.CR-19-0076","article-title":"Urgent control of rapid atrial fibrillation by landiolol in patients with acute decompensated heart failure with severely reduced ejection fraction","volume":"1","author":"Iwahashi","year":"2019","journal-title":"Circ Rep"},{"key":"2022061314500976500_suac023-B22","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1253\/circj.CJ-18-1131","article-title":"Differential effectiveness of landiolol between atrial fibrillation and atrial flutter\/atrial tachycardia patients with left ventricular dysfunction","volume":"83","author":"Oka","year":"2019","journal-title":"Circ J"},{"key":"2022061314500976500_suac023-B23","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jjcc.2019.05.012","article-title":"A prospective observational survey on landiolol in atrial fibrillation\/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey","volume":"74","author":"Yamashita","year":"2019","journal-title":"J Cardiol"},{"key":"2022061314500976500_suac023-B24","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1536\/ihj.20-256","article-title":"Comparison of landiolol and digoxin as an intravenous drug for controlling the heart rate in patients with atrial fibrillation and severely depressed left ventricular function","volume":"61","author":"Shinohara","year":"2020","journal-title":"Int Heart J"},{"key":"2022061314500976500_suac023-B25","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12325-014-0111-2","article-title":"Impacts of patient characteristics on the effectiveness of landiolol in AF\/AFL patients complicated with LV dysfunction: subgroup analysis of the J-Land study","volume":"31","author":"Kinugawa","year":"2014","journal-title":"Adv Ther"},{"key":"2022061314500976500_suac023-B26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1253\/circj.CJ-19-0661","article-title":"Open-label two-dose pilot study of landiolol for the treatment of atrial fibrillation\/atrial flutter in Caucasian patients","volume":"84","author":"Stix","year":"2019","journal-title":"Circ J"},{"key":"2022061314500976500_suac023-B27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1067\/mcp.2000.108733","article-title":"Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias","volume":"68","author":"Atarashi","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"2022061314500976500_suac023-B28","article-title":"First experience with the ultra-short acting intravenous cardioselective beta-blocker landiolol on the intensive care unit in Germany: a case series","volume":"107","author":"Weinmann","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"2022061314500976500_suac023-B29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13054-021-03470-3","article-title":"Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients","volume":"25","author":"Hariri","year":"2021","journal-title":"Crit Care"},{"key":"2022061314500976500_suac023-B30","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1536\/ihj.19-420","article-title":"Successful combination of landiolol and levosimendan in patients with decompensated heart failure","volume":"61","author":"Dabrowski","year":"2020","journal-title":"Int Heart J"},{"key":"2022061314500976500_suac023-B31","first-page":"A3320","article-title":"Landiolol vs esmolol on hemodynamic response during weaning of post-operative ICU patients with heart failure","volume":"58","author":"Anifanti","year":"2021","journal-title":"Eur Respir J"},{"key":"2022061314500976500_suac023-B32","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ehf2.13763","article-title":"Effect of landiolol in patients with tachyarrhythmias and acute decompensated heart failure (ADHF): a case series","volume":"9","author":"Ditali","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2022061314500976500_suac023-B33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/eurheartj\/ehr239","article-title":"A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?","volume":"33","author":"Verschuren","year":"2012","journal-title":"Eur Heart J"},{"key":"2022061314500976500_suac023-B34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/FPC.0b013e32835afde6","article-title":"The common Arg389gly ADRB1 polymorphism affects heart rate response to the ultra-short-acting \u03b2(1) adrenergic receptor antagonist esmolol in healthy individuals","volume":"23","author":"Muszkat","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"2022061314500976500_suac023-B35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FJC.0000000000000495","article-title":"Pharmacodynamic and -kinetic behavior of low-, intermediate-, and high-dose Landiolol during long-term infusion in whites","volume":"70","author":"Krumpl","year":"2017","journal-title":"J Cardiovasc Pharmacol"},{"key":"2022061314500976500_suac023-B36","first-page":"1319","article-title":"Urgent control of rapid atrial fibrillation using landiolol in patients with acute decompensated heart failure with reduced or preserved left ventricular ejection fraction","volume":"37","author":"Ozaki","year":"2016","journal-title":"Eur Heart J"},{"key":"2022061314500976500_suac023-B37","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1161\/CIRCRESAHA.114.303772","article-title":"Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy","volume":"114","author":"Chen","year":"2014","journal-title":"Circ Res"},{"key":"2022061314500976500_suac023-B38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1253\/circrep.CR-20-0119","article-title":"Mid-term prognosis after landiolol treatment in atrial fibrillation\/atrial flutter patients with chronic heart failure- a prospective observational survey (AF-CHF landiolol survey).","volume":"3","author":"Yamashita","year":"2020","journal-title":"Circ Rep"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/24\/Supplement_D\/D11\/44045032\/suac023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/24\/Supplement_D\/D11\/44045032\/suac023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T14:51:05Z","timestamp":1655131865000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/24\/Supplement_D\/D11\/6607625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":38,"journal-issue":{"issue":"Supplement_D","published-online":{"date-parts":[[2022,6,13]]},"published-print":{"date-parts":[[2022,6,13]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suac023","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,6,1]]}}}